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Chemokines were initially identified as bioactive substances, which control the trafficking of inflammatory cells including
granulocytes and monocytes/macrophages. Moreover, chemokines have profound impacts on other types of cells associated with
inflammatory responses, such as endothelial cells and fibroblasts. These observations would implicate chemokines as master
regulators in various inflammatory responses. Subsequent studies have further revealed that chemokines can regulate themovement
of a wide variety of immune cells including lymphocytes, natural killer cells, and dendritic cells in both physiological and
pathological conditions. These features endow chemokines with crucial roles in immune responses. Furthermore, increasing
evidence points to the vital effects of several chemokines on the proliferative and invasive properties of cancer cells. It is widely
acknowledged that cancer develops and progresses to invade and metastasize in continuous interaction with noncancerous cells
present in cancer tissues, such as macrophages, lymphocytes, fibroblasts, and endothelial cells. The capacity of chemokines to
regulate both cancerous and noncancerous cells highlights their crucial roles in cancer development and progression. Here, we will
discuss the roles of chemokines in carcinogenesis and the possibility of chemokine targeting therapy for the treatment of cancer.
1. Introduction
Chemokines are heparin-binding proteins with 4 cysteine
residues in the conserved positions [1]. Two intermolecular
disulfide bonds are formed between the first and third
cysteines and between the second and fourth cysteines.
These bonds lead to the formation of triple-stranded 𝛽-
sheet structures, while the carboxyl-terminal region forms
a 𝛼-helix form [2]. This accounts for their similar three-
dimensional structure despite their low overall sequence
similarities. Chemokines exert their biological activities by
binding their corresponding receptors, which belong to G-
protein coupled receptor (GPCR) with 7-span transmem-
brane portions [1]. Thus, the target cell specificity of each
chemokine is determined by the expression pattern of its
cognate receptor (Table 1). Moreover, chemokines can bind
to proteoglycans and glycosaminoglycans with a high avidity,
because the carboxyl-terminal region is capable of binding
heparin. Consequently, most chemokines are produced as
secretory proteins, but upon their secretion, they are immobi-
lized on endothelium cells and/or in extracellular matrix by
interacting with proteoglycans and glycosaminoglycans [2].
The immobilization facilitates the generation of a concentra-
tion gradient, which is important for inducing the target cells
to migrate in a directed way.
Chemokines are structurally divided into 4 subgroups,
namely, CXC, CC, CX3C, and C [1]. The first 2 cysteines
are separated by 1 and 3 amino acids in CXC and CX3C
chemokines, respectively, while the first 2 cysteines are
adjacent in CC chemokines. The C chemokines lacks the
second and fourth cysteines [1]. The CXC chemokines are
further grouped based on the presence or the absence of a
3-amino acid sequence, glutamic acid-leucine-arginine (the
ELR motif), immediately preceding the CXC sequence [3].
Chemokines can be functionally classified as inflammatory,
homeostatic, or both, based on their expression patterns
[4]. Various types of inflammatory stimuli induce abun-
dantly the expression of inflammatory chemokines to induce
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2014, Article ID 170381, 15 pages
http://dx.doi.org/10.1155/2014/170381
2 Mediators of Inflammation
Table 1: The human chemokine system.
Chemokine receptor Chemokines Receptor expression in
Leukocytes Epithelium Endothelium
CXCR1 CXCL6, 8 PMN + −
CXCR2 CXCL1, 2, 3, 5, 6, 7, 8 PMN + +
CXCR3 CXCL4, 9, 10, 11 Th1, NK − +
CXCR4 CXCL12 Widespread + +
CXCR5 CXCL13 B − −
CXCR6 CXCL16 Activated T + −
CXCR7 (ACKR3) CXCL12, CXCL11 Widespread + +
Unknown CXCL14 (acts on monocytes)
CCR1 CCL3, 4, 5, 7, 14, 15, 16, 23 Mo, M𝜙, iDC, NK + +
CCR2 CCL2, 7, 8, 12, 13 Mo, M𝜙, iDC, NKactivated T, B + +
CCR3 CCL5, 7, 11, 13, 15, 24, 26, 28 Eo, Ba, Th2 − +
CCR4 CCL2, 3, 5, 17, 22 iDC, Th2, NK, T, M𝜙 − −
CCR5 CCL3, 4, 5, 8 Mo, M𝜙, NK, Th1activated T + −
CCR6 CCL20 iDC, activated T, B + −
CCR7 CCL19, 21 mDC, M𝜙, na¨ıve Tactivated T + −
CCR8 CCL1, 4, 17 Mo, iDC, Th2, Treg − −
CCR9 CCL25 T + −
CCR10 CCL27, 28 Activated T, Treg + −
Unknown CCL18 (acts on mDC and na¨ıve T)
CX3CR1 CX3CL1 Mo, iDC, NK, Th1 + −
XCR1 XCL1, 2 T, NK − −
Miscellaneous Scavenger receptors for chemokines
Duffy antigen (ACKR1) CCL2, 5, 11, 13, 14
CXCL1, 2, 3, 7, 8
D6 (ACKR2) CCL2, 3, 4, 5, 7, 8, 12
CCL13, 14, 17, 22
CCRRL1 (ACKR4) CCL19, CCL21, CCL25
Leukocyte anonyms are as follows. Ba: basophil, Eo: eosinophil, iDC: immature dendritic cell, mDC: mature dendritic cell, Mo: monocyte, M𝜙: macrophage,
NK: natural killer cell, Th1: type I helper T cell, Th2: type II helper T cell, and Treg: regulatory T cell.
the infiltration of inflammatory cells such as granulocytes
and monocytes/macrophages. Representative inflammatory
chemokines are CXC chemokines with ELRmotif and CCL2.
On the contrary, homeostatic chemokines are expressed
constitutively in specific tissues or cells. They have a crucial
role in organogenesis of various organs including lymph
nodes, arising from their key roles in stem cell migration.
Moreover, most homeostatic chemokines can control the
movement of lymphocytes and dendritic cells and eventually
adaptive immunity.
The human and mouse genomes contain over 44 and
38 different chemokine genes, respectively [5]. There is a
difference in gene numberswith some ambiguities of ortholo-
gous relationship between the human and mouse chemokine
family. These observations would indicate species-specific
expansions and contractions in chemokine genes, resulting
from their rapid evolution. A prominent difference is found
in one major chemokine, CXCL8, and its receptors, CXCR1
and CXCR2. Mice and rats do not possess a homolog of
the CXCL8/IL-8 gene, which is present in other species
including humans, rabbits, cats, and dogs [5]. Moreover,
the CXCR1 and CXCR2 genes encode functional receptor
proteins in humans, whereas there still remains a question on
the presence of functional CXCR1 gene in mice or rats [6].
Furthermore, humans and mice exhibit different expression
patterns also in other chemokine receptors such as CCR1 [7].
These observations should be taken into consideration when
the findings obtained with mouse models are extrapolated
into human conditions.
Here, we will review the potential roles of chemokines
in tumor development and progression by focusing on their
effects on noncancerous and cancerous cells. We will further
discuss the potential of chemokine targeting therapy for
cancer treatment.
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2. Effects on Noncancerous Cells
2.1. Leukocytes. Since the first description by Virchow more
than a century ago, it is widely acknowledged that leukocytes
are present in both the tumor areas and the tumor-supporting
stroma [8]. Moreover, leukocytes might account for up
to 50% of the tumor mass, the most predominant subset
being macrophages. Tumor-associated macrophages (TAMs)
are derived mostly from circulating monocytes which are
attracted into tumor sites by locally produced chemotactic
factors, such as CCL2, CCL5, CCL7, CCL8, and CXCL12,
and macrophage colony stimulating factor (M-CSF) [8].
Among these chemotactic factors, CCL2 is presumed to
play an important role in TAM recruitment [8, 9]. Repeated
dextran sodium sulfate (DSS) solution ingestion causes the
development of multiple colonic tumors in mice, which
received a prior administration of azoxymethane (AOM).
The resultant colonic tumors contain a large number of
monocytes/macrophages expressing cyclooxygenase (COX)-
2, an enzyme crucially involved in colon carcinogenesis [10].
Abundant CCL2 is detected in colon tissues, and CCL2
blockade reduces the infiltration of CCR2-positive COX-2
expressing monocytes/macrophages and eventually colonic
tumor development and progression [10].
TAMs produce various growth factors such as vascular
endothelial growth factor (VEGF) and fibroblast growth
factor (FGF) in addition to prostaglandin [8, 9]. Monocytes
are recruited by CCL2 to pulmonary metastatic sites of
murine breast cancer and promote the extravasation of tumor
cells, a necessary step formetastasis, in a process that requires
monocyte-derived VEGF [11]. Moreover, TAMs exhibit the
properties of M2-polarized macrophages and are capable of
producing immunosuppressive molecules including IL-10,
transforming growth factor (TGF)-𝛽, and arginase [12].These
properties endow TAMs with an immunosuppressive capac-
ity. Thus, TAMs can promote tumor progression through
the production of growth factors and the suppression of
antitumor immunity (Figure 1).
Tumor tissues contain myeloid-derived suppressor cells
(MDSCs), which can suppress adaptive immunity. MDSCs
are characterized by the coexpression of the myeloid-cell
lineage differentiation antigen Gr-1 and CD11b in mice, while
they are defined as CD14−CD11b+ cells or as cells that express
the common myeloid marker CD33 but lack the expression
of mature myeloid and lymphoid markers in humans [13].
MDSCs contain abundantly immunosuppressive enzymes,
arginase 1 and inducible NO synthetase (iNOS), and produce
immunosuppressive cytokines such as TGF-𝛽1 and IL-10,
thereby inhibiting the T-cell response [13]. CCL2 recruits
MDSCs in several types of mouse cancer, including Lewis
lung carcinoma, meth A sarcoma, melanoma, and lymphoma
[14]. However, CCR2 deficiency results in the conversion of
theMDSCphenotype frommacrophage lineage to neutrophil
lineage without affecting tumor growth [15]. MDSCs, partic-
ularly granulocytic ones, express CXCR2 and are plentifully
present in colonic tumors developed after the combined
treatment of AOM and DSS [16]. CXCR2 ligands, such as
CXCL1, CXCL2, and CXCL5, are present abundantly in the

























Figure 1: Chemokines acting on TAMs and MDSCs.
suppresses tumorigenesis through inhibiting MDSC infiltra-
tion [16] (Figure 1).
Regulatory T (Treg) cells have a crucial role in the
maintenance of immunological self-tolerance [17]. A large
number of Treg cells often infiltrate into tumors and systemic
removal of Treg cells enhances natural as well as vaccine-
induced antitumor T-cell immunity. Treg cells express CCR4,
and its ligand, CCL22, regulates intratumoral Treg infiltration
in various tumors [17]. Hypoxia induces the expression of
another chemokine, CCL28, in tumor sites. CCL28 promotes
angiogenesis and recruits Treg cells, thereby also propagating
immune tolerance [18] (Figure 2).
Bindea and colleagues demonstrated that T follicular
helper (Tfh) cells and B cells infiltrated tumor sites of human
colorectal cancer patients, along with tumor progression [19].
Moreover, the numbers of B cells were associated with pro-
longed survival. Furthermore, when colon cancer cells were
endoscopically injected into the colon submucosa, CXCL13
injection reduced tumor formation, whereas the deficiency
in CXCR5 gene, a receptor for CXCL13, accentuated tumor
formation [19]. Thus, the CXCL13/CXCR5 axis might be
pivotal factors for the Tfh/B cell infiltration into tumor sites
and subsequent tumor formation.
Antitumor responses are attributable to tumor infiltrat-
ing lymphocytes (TILs), particularly cytotoxic T lympho-
cytes (CTLs) [20]. CTLs can specifically recognize tumor-
associated antigens (TAAs) and attack tumor cells in humans
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Figure 3: Chemokines acting on dendritic cells at different maturation stages.
as well as in mice [21] (Figure 2). In this process, antigen-
presenting cells can deliver TAAs and prime TAA-specific
T cells. Dendritic cells (DCs) are professional antigen-
presenting cells and can express on their cell surface major
histocompatibility complex (MHC) class I and II molecules
and costimulatory molecules, all of which assist in T-cell
activation [21]. Immature DCs are distributed in almost
every peripheral tissue and express several chemokine recep-
tors including CCR1, CCR2, CCR4, CCR5, CCR6, CCR8,
and CXCR4, with a high capacity to endocytose various
materials [22]. DCs capture exogenous and endogenous
antigens including tumor cell-derived antigens in periphery
(Figure 3). When DCs capture antigens in the presence of
inflammatory stimuli such as toll-like receptor-mediated
signals, they change to a mature state and lose endocytosis
ability. They start to express a limited set of chemokine
receptors, CCR7 and CXCR4, and migrate into the T-cell
areas of regional lymph nodes via afferent lymphatic venules
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under the guidance of chemokines [23] (Figure 3). Indeed,
the appearance of apoptotic tumor cells induces themigration
of dendritic cells to the draining lymph nodes and eventually
generates a specific cytotoxic T lymphocyte population in
the draining lymph nodes by utilizing the CCL3-CCR5/CCR1
axis [24]. On the contrary, DCs fail to express costimulatory
molecules and to present antigens efficiently if they capture
antigens in the absence of inflammatory cues. Mature DCs
exhibit enhanced expression of costimulatory molecules and
process the antigens into the peptides. The resultant peptides
are presented to T cells in conjunction with MHCmolecules,
in the regional lymph nodes, to induce primary immune
responses [23] (Figure 3).
Once generated in the regional lymph nodes, TAA-
specific CTLs should migrate to tumor sites to kill tumor
cells. Numerous clinical studies have indicated that the
intratumoral presence of CD3+ or CD8+ lymphocytes has
a positive prognostic influence on survival [25]. Several
chemokines can regulate the migration of TILs, particularly
CTLs, into tumor sites. CXCR3 is deemed to be a major
chemokine receptor expressed by TILs. In a mouse model,
increased expression of ligands for CXCR3, CXCL9, and
CXCL10 can elicit antitumor response accompanied with an
enhanced infiltration of CD4+ and CD8+ lymphocytes [26].
Consistently with this observation, in human gastric and
colorectal cancer, TILs express CXCR3 (Figure 2) [27–29].
Moreover, high levels of CXCL9 and CXCL10 are produced
by stromal cells, mainly macrophages [28]. CD8+ TILs
also express another chemokine receptor, CCR5 [27, 29].
Concomitantly, CD8+ TIL numbers correlate well with the
expression of CCL5, a ligand for CCR5, by tumor tissues [29].
TILs express additional chemokine receptor, CX3CR1, and
the expression of its ligand, CX3CL1, is elevated in tumor cells
in colorectal cancer tissues [30]. Furthermore, the expression
level of CXCL16 also correlates with CD4+ and CD8+ TIL
as well as numbers with a better prognosis although cells
expressing CXCR6, a receptor for CXCL16, are not identified
[31]. Thus, CXCL9, CXCL10, CXCL16, CCL5, and CX3CL1
can be used to efficiently mobilize CTLs from regional lymph
nodes to tumor tissues with an objective to enhance CTL-
mediated tumor destruction.
Natural killer (NK) cells are unconventional lymphocytes,
which can in vitro kill a broad range of tumor cells of
both hematopoietic and nonhematopoietic origin by utilizing
perforin and secreting interferon (IFN)-𝛾 [32]. Moreover,
in vivo, mouse NK cells can eliminate many transplantable
and spontaneous tumors. NK cells express distinct sets of
chemokine receptors (Table 1). NK cells migrate to lymph
nodes mainly by utilizing CXCR3, while their migration to
the inflamed tissues including tumor sites involves CCR1,
CCR2, CCR5, CXCR3, and CX3CR1 (Figure 2) [33].Thus, the
ligands for these receptors can regulate NK cell trafficking
and augment their functions. However, in colorectal tumor
tissues, NK cells are scarce despite a significant lymphocyte
infiltration, even in the presence of high levels of CXCL9,
CXL10, CCL3, CCL4, CCL5, and CX3CL1 [34].Thus, NK cell
migration into tumor tissues may be impaired early in the
course of tumor development by themechanism that does not
affect CTL trafficking.
We recently succeeded in causing chronic myelogenous
leukemia (CML)- like pathology by direct transplantation of
BCR-ABL gene-transduced leukemia initiating cells (LICs)
into the bone marrow cavity of nonirradiated mice [35].
We further observed that BCR-ABL+lineage−c-kit− immature
leukemia cells produced high levels of CCL3, which pro-
moted the development of CML. Conversely, the ablation
of CCL3 gene in LICs dramatically inhibited the devel-
opment of CML and concomitantly reduced recurrence
after the cessation of a short-term tyrosine kinase inhibitor
treatment. Moreover, normal hematopoietic stem/progenitor
cells (HSPCs) can directly impede the maintenance of LICs
in bone marrow in the absence of CCL3 signal. These
observations would indicate that leukemia cell-derived CCL3
expels normal HSPCs from bone marrow to make spaces for
leukemia cells to survive [35].
2.2. Endothelial Cells. Neovascularization is crucial for tumor
growth, progression, and metastasis [36]. The ELR-motif-
positive CXC chemokines, CXCL1, CXCL2, CXCL3, CXCL5,
CXCL6, CXCL7, and CXCL8, directly promote the migra-
tion and proliferation of endothelial cells and eventually
neovascularization, mainly by interacting with CXCR2 but
not with CXCR1 [37]. CXCL12 is not an ELR-positive CXC
chemokine but has a potent angiogenic activity [38]. Three
CC chemokines, CCL2, CCL11, and CCL16, have also been
implicated in tumor neovascularization [39–41]. CCR2, a
specific receptor for CCL2, is expressed by endothelial cells
and CCL2 exerts its angiogenic activity in a membrane
type 1- (MT1-) matrix metalloproteinase- (MMP-) dependent
manner [39] (Figure 4).
CXCL4 and interferon-inducible ELR-negative CXC
chemokines such as CXCL9, CXCL10, and CXCL11 inhibit
the angiogenesis induced by ELR-motif-positive CXC
chemokines, VEGF, and bFGF [42, 43] by interacting with
a common receptor, CXCR3 (Figure 4). Moreover, the
Duffy antigen has been shown to suppress the angiogenic
effects of the ELR-motif-positive CXC chemokines, as it can
sequester the ELR-motif-positive CXC chemokines without
eliciting any intracellular signals [44]. Thus, the balance
between proangiogenic and antiangiogenic chemokines may
determine the degree of tumor neovascularization.
TAMs and MDSCs contributed to tumor angiogenesis
by producing a wide variety of angiogenic factors such
as VEGF, TGF-𝛽, CXCL8, platelet-derived growth factor
(PDGF), and MMPs such as MMP-2 and MMP-9 [8, 9].
Several chemokines, particularly CCL2, can induce tumor
angiogenesis by attracting TAMs and MDSCs. Moreover,
recruited TAMs and MDSCs can acquire endothelial cell
phenotypes and be incorporated into the newly formed
vascular structure (Figure 4) [45]. Endothelial cell-derived
ELR-motif-positive CXC chemokines, especially CXCL6,
induce angiogenesis in gastrointestinal cancer by recruiting
neutrophils [46].
2.3. Fibroblasts and Other Cells. Fibroblasts present in
tumor tissues are designated as cancer-associated fibroblasts
(CAFs). CAFs can produce tumor-promoting molecules



































Figure 4: Chemokines acting on tumor neovascularization.
such as TGF-𝛽, FGF, hepatocyte growth factor (HGF),
and EGF [47]. The proposed cellular sources of CAFs
include locally resident fibroblasts, cells undergoing
epithelial-mesenchymal transition (EMT), cells undergoing
endothelial-mesenchymal transition (EndMT), or bone
marrow- (BM-) derived mesenchymal stem cells (MSCs)
[48]. In a mouse gastric cancer model, it is estimated that
BM-derivedMSCs can contribute asmuch as 25% to the CAF
population [49]. On the contrary, in a mouse lung metastasis
model, BM-derived cells do not significantly contribute to
fibroblast accumulation in lungs [50].
In a mouse gastric cancer model, CXCL12 expression
was found to be enhanced together with enhanced fibro-
sis in tumor sites [49]. Because MSCs express CXCR4
and CXCR7 and migrate to their ligand, CXCL12, the
CXC12-CXCR4/CXCR7 axis may regulate the accumulation
of fibroblasts and consequent fibrosis development [48].
Moreover, CAFs present in various types of cancer produce
CXCL12, and the producedCXCL12 promotes the angiogenic,
proliferative, and migratory properties of tumor cells. CAFs
produce CCL2, CCL5, CCL7, CXCL8, and CXCL14 and
these chemokines promote tumor progression mainly by
enhancing the motility of tumor cells [48].
In a mouse lung metastasis model, HGF-expressing
fibroblasts were found to be increased in the lungs [50]. Lung
fibroblasts express CCR5, and genetic deletion of CCR5 or
its ligand, CCL3, attenuates intrapulmonary lung metastasis
formation along with reduced fibroblast accumulation and
HGF expression [50]. We recently observed that fibroblast
accumulation was required for full-blown progression of
chronic colitis-associated colon cancer, in addition to inflam-
matory cell infiltration. Moreover, fibroblast accumulation in
colon tissues was regulated by the CCL3-CCR5 axis.
When activated, hepatic stellate cells (HSCs) express a
marker of myofibroblasts, 𝛼-smooth muscle actin (𝛼-SMA).
𝛼-SMA-positive HSCs secrete CXCL12 similarly as CAFs do
[51]. Moreover, in a mouse liver metastasis model, tumor-
derived CCL2 was found to induce 𝛼-SMA-positive HSCs to
accumulate at tumor sites and to express MMP-2. Genetic
ablation of CCR2 markedly attenuates tumor formation with
reduced HSC accumulation and MMP-2 expression [52].
Thus, CCR2-mediated signals may regulate the trafficking
and functions of HSCs, thereby inducing liver metastasis.
3. Direct Effects on Cancerous Cells
The tyrosine kinase, RET, is a prototypic transforming onco-
gene in human papillary thyroid carcinoma and induces the
expression of several chemokines including CCL2, CCL20,
ELR-motif-positive CXC chemokines, and CXCL12, and
CXCR4 [53]. The CXCR4 gene can further be transactivated
by the activation of hypoxia-inducible factor- (HIF-) 1𝛼,
arising either from loss of the von-Hippel-Lindau tumor
suppressor (VHL) or due to the hypoxic conditions observed
frequently in tumor tissues [54]. Moreover, components of
the Ras-Raf signaling pathway can activateNF-𝜅B [55], which
can lead to enhanced expression of chemokines, including
CXCL1, CXCL8, and CCL2 [56]. Thus, even in the absence
of direct oncogene activation, NF-𝜅B and HIF activation can
induce the expression of chemokines and their receptors, in
tumor tissues.
The term “cellular senescence” has been used to denote
a stable and long-term loss of proliferative capacity, despite
continued viability and metabolic activity [57]. Activation
of oncogenes, particularly Ras, induces cellular senescence
which is designated as oncogene-induced senescence (OIS).
OIS serves as a potent barrier against oncogenic transfor-
mation by suppressing the unscheduled proliferation of early
neoplastic cells [57]. Moreover, cells undergoing OIS secrete
CXCR2-binding chemokines and IL-6 through the activation
































Figure 5: Effects of chemokines on tumor cells.
of 2 proinflammatory transcription factors, C/EBP-𝛽 andNF-
𝜅B [58, 59]. CXCL8/IL-8 specifically colocalizes with arrested
p16INK4A-positive epithelium in human colon adenomas
[58]. Furthermore, the reduction of CXCR2 expression on
tumor cells alleviates OIS and diminishes the DNA-damage
response, while ectopic expression of CXCR2 results in
premature senescence via a p53-dependent mechanism [59].
Thus, CXCR2-binding chemokines can promote the arrest
of cellular growth and eventually delay the early phase of
tumorigenesis (Figure 5).
EMT is indispensable for embryogenesis [60]. EMT
induces epithelial cells to lose the expression of components
of cell polarity, such as E-cadherin, and reciprocally to
express mesenchymal components of the cytoskeleton and
to eventually acquire the motility and scattering properties.
EMT is presumed to be associated with the capacity of tumor
cells to invade and metastasize [60]. Prolonged exposure to
TGF-𝛽 induces rat hepatocellular carcinoma cells to exhibit
a mesenchymal phenotype, and a higher migratory and inva-
sive capacity, coincident with increased CXCR4 expression,
and these phenotypic changes are reduced by a CXCR4
antagonist [61]. Likewise, the expression of CXCL8 and its
receptor, CXCR1, is induced in a human colon cancer cell line
undergoing TGF-𝛽-driven EMT [62]. EMT in cancer cells
can be initiated by overexpression of several transcription
factors, including Twist, Snail, and Brachyury [60]. Over-
expression of Brachyury causes EMT in human pancreatic
cancer cell lines, along with enhanced expression of CXCL8,
CCL5, and CXCL1, while the inhibition of CXCL8 signaling
pathway abrogates Brachyury-induced EMT phenotypes and
invasive capacity of cells [63]. These observations suggest the
crucial roles of several chemokines in EMT, an indispensable
step for the malignant progression of cancer (Figure 5).
Chemokine receptor engagement can also activate the
mitogen-activated protein (MAP)/Erk kinase pathway [64],
leading to gene expression and cell proliferation (Figure 5).
Human gastric cancer cell lines possess CXCR1 and CXCR2
and express epidermal growth factor (EGF) receptor, MMP-
9, and VEGF, in response to CXCL8 [65]. The same pathway
is utilized to promote proliferation of esophageal cancer cells
[66] and melanoma cells [67].
In addition to the CXCL8 axis, several chemokines
have impacts on proliferation and survival of tumor cells.
CCR6 and CXCR6 promote the proliferation of colorectal
cancer cells [68] and prostate cancer cells [69], respec-
tively. Moreover, CCR10 activation in melanoma causes
phosphatidylinositol-3-kinase- (PI3K-) mediated protection
of tumor cells from apoptosis [70]. Similar observations are
obtained on CCR7 activation in squamous cell carcinoma of
the head and neck [71] (Figure 1). On the contrary, CCR5
blockade can enhance the proliferation of breast cancer cells,
which express wild-type p53 [72]. Furthermore, disease-
free survival is shorter in breast cancer patients bearing
the CCR5Δ32 allele with a premature stop codon than in
CCR5 wild-type patients; this holds true only in wild-type
p53-expressing tumors [72]. Likewise, human hepatocellular
carcinoma (HCC) cells express CCR1 and its ligands can
affect the functions of human HCC cell lines [73].
CXCR4 is the most commonly detected chemokine
receptor in tumor cells [38]. CXCR4 has an important role
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in the proliferation of various cancer cells including ovarian,
glioma, melanoma, lung, renal, and thyroid cancer cells [38,
74]. The CXCL12/CXCR4 axis delivers surviving signals to
hepatocellular carcinoma cells, ovarian carcinoma cells, and
chronic leukemia cells, while CXCR4 blockade induces the
apoptosis of these malignant cells [38, 61, 75] (Figure 5).
CXCL12 expression correlates well with lower apoptosis in
human myelodysplastic syndrome [76].
Chemokines can regulate the migration of tumor cells.
CXCR4-expressing cells canmigrate in vitro towards CXCL12
[77]. CCR7, CCR9, CXCR1, and CXCR2 are also detected
in tumor cells and their ligands can induce the chemo-
taxis of the corresponding receptor-expressing cells [78, 79].
These chemokines can serve as inducers of invasion within
the primary tumor and dissemination to distant organs
(Figure 5). Moreover, human pancreatic ductal adenocarci-
noma (PDAC) cells express CX3CR1 andCX3CL1 abundantly
and the CX3CR1/CX3CL1 axis can regulate intraneural inva-
sion of PDAC [80]. Adult T-cell leukemia (ATL) cells express
frequently CCR4 and can migrate in vitro to CCL17 and
CCL22, ligands for CCR4 [81].TheCCL17/CCL22-CCR4 axis
may account for the frequent infiltration of ATL into skin
and lymph nodes, where CCL17 and CCL22 are abundantly
expressed.
Circulating tumor cells (CTCs) are presumed to be a
source ofmetastasizing tumor cells, but they can also colonize
at their original site [82]. This process, which is called as
tumor self-seeding, can accelerate tumor growth and angio-
genesis. CTCs produce ELR-motif-positive CXC chemokines
including CXCL8 and CXCL1, and these chemokines eventu-
ally promote self-seeding [82].
Several models have been proposed to explain the molec-
ular mechanisms underlying the enhancement and regula-
tion of metastasis by the chemokines. Specific chemokine
receptor-expressing tumor cells may migrate to organs with
high expression levels of the corresponding chemokines
along a concentration gradient [77]. This hypothesis may
explain the tissue tropism observed in certain types of
cancer, but there is little evidence to indicate the presence
of chemokine concentration gradients between primary and
metastatic sites. A transcellular CCR7 ligand gradient can
be created when cancer cells produce CCR7 ligands under
flow conditions and the resultant gradient can be the basis
of lymphatic metastasis [83]. Thus, cancer cells themselves
may actively promote their own metastasis and tropism by
producing chemokines. Another plausible explanation is that
the arrival of tumor cells in a specific organ is passive and
that chemokine receptor expression provides tumor cells
with an advantage to survive and grow in a different ligand-
rich metastatic microenvironment [84]. Moreover, CXCL12
and a CCR7 ligand, CCL21, can induce the resistance of
cancer cells to anoikis, which is a major hindrance to the
metastatic spread of various types of cancer, by regulating
proapoptotic Bmf and antiapoptotic Bcl-xL proteins [85].
Thus, chemokines may accelerate metastasis by promoting
tumor cell proliferation or preventing tumor cell death.
Thus, chemokines can prevent tumorigenesis in the early
phase by inducing cellular senescence while they can also
promote invasion and metastasis by inducing EMT and
enhancing the motility and survival of tumor cells (Figure 5).
4. Potential of Chemokine Targeting Therapy
as Cancer Treatment
4.1. Chemokine-Mediated Enhancement in Tumor Immunity.
Theestablishment of tumor immunity is amultistage process:
migration of DCs to tumor sites, capture of TAAs by DCs,
migration of DCs to regional lymph nodes, antigen presen-
tation to effector cells by DCs in regional lymph nodes, and
migration of effector cells to tumor sites (Figure 6) [21, 22].
Chemokines have profound impacts on tumor immunity,
particularly migration steps.
Immature dendritic cells move to the tumor tissues to
phagocytose apoptotic tumor cells, capture tumor-associated
antigens (TAAs), and migrate to draining lymph nodes,
where DCs present antigens to induce specific CTLs [21–
23]. Tumor-infiltrating DCs expressed CCR1 and CCR5,
and a ligand for these receptors, CCL3, was abundantly
detected in mouse bearing HCC [24]. Mirroring the capacity
of CCL3 to mobilize CCR1- or CCR5-expressing immature
DCs to peripheral blood from bone marrow [86], systemic
administration of CCL3 increased the numbers of DCs
in peripheral blood and tumor tissues and concomitantly
augmented antitumor effects after radiofrequency ablation of
murine HCCs [87]. Thus, CCL3 may be effective to enhance
tumor immunity by attracting immature DCs to dying tumor
cells.
CCL19 and CCL21, ligands for CCR7, can regulate DC
migration to lymph nodes for antigen presentation to naı¨ve
T cells, which also utilize CCL19 and/or CCL21 to enter T-
cell zone [88], and they can additionally attract NK cells
to the lymph node. As a consequence, when CCL21 was
injected into a regional lymph node of SV40-transgenic mice
that developed bilateral multifocal lung adenocarcinomas, it
increased CD4+ and CD8+ lymphocytes as well as DCs at
lymph nodes and tumor sites and eventually led to a marked
reduction in tumor burdens with enhanced survival [89].
Similar results were also obtained when CCL19 was injected
intranodally into SV40-transgenic mice [90].
Low clinical efficacy of DC-based vaccines can be
explained by a very limited capacity of ex vivo generated DC
to move from the injected sites to draining lymph nodes [91].
In order to circumvent these problems, DCs are genetically
modified to express CCL19 and CCL21. Indeed, intratumoral
injection ofCCL21 gene-modifiedDCs resulted inmore effec-
tive tumor growth inhibition than unmodified control DCs
[92], together with intratumoral accumulation of DCs and T
cells [93]. Moreover, even when CCL21 gene-modified DCs
were pulsed with tumor lysates and subsequently injected
subcutaneously to tumor-free sites in tumor-bearing mice,
it elicited a good antitumor response [92]. These promising
preclinical results have led to ongoing phase I clinical trials
[94].
Intratumoral administration of CCL21 gene-modified
DCs reduced a tumor burden in spontaneous murine lung
carcinoma, accompanied with extensive T-cell infiltration























Figure 6: Tumor immunity generation process.
and the enhanced IFN-𝛾, IL-12, CXCL9, and CXCL10 expres-
sion [95]. Moreover, in vivo depletion of either CXCL9
or CXCL10 significantly reduced the antitumor efficacy of
CCL21 gene-modified DCs, probably because CXCR3 is
highly expressed by activated effector CD8+ T cells and
Th1-type CD4+ T cells [96]. CXCL10 gene transduction
into tumor cells had few effects on in vitro tumor cell
proliferation but in vivo elicited a potent T-cell-dependent
antitumor response [97]. Likewise, tumor cells expressing
CXCL10 induced the infiltration of tumor-specific cytotoxic
T cells into the tumor site [98].Moreover, tumor cells induced
these cytotoxic T cells to proliferate and to produce high
level of IFN-𝛾, while CXCL10 expanded these tumor-specific
T cells [98]. Similar observations were obtained on gene
transduction of another ligand for CXCR3, CXCL11, into
tumor cells [99]. Moreover, as T cells rapidly acquire CXCR3
expression upon activation with IL-2 [96], combined strategy
of systemic IL-2 with intratumor CXCL9 administration was
proven to be more efficacious than either cytokine alone, for
augmenting tumor-associated immunity [26].Thus, CXCR3-
binding chemokines can be utilized to redirect the migration
of effector T cells to tumor sites.
CCL2 was initially isolated as a factor which can also
augment monocyte-mediated tumor cytostatic activity [100].
Indeed, tumor formation was suppressed in vivo but not in
vitro when the tumor was genetically engineered to express
CCL2 gene [101]. CCL2-expressing cells elicited a predomi-
nantly monocytic infiltrate at the site of injection, suggesting
the roles of infiltrating monocytes in tumor rejection process
[101]. In another tumor models, CCL2 gene transduction
into tumor cells retarded tumor growth in vivo by inducing
NK infiltration into tumor sites [102], because NK cells
express CCR2, a receptor for CCL2 (Table 1). Moreover, NK
cell infiltration was associated with elevated Th1 response
in tumor sites [103], suggesting that CCL2 can regulate the
infiltration and activation of Th1 cells in tumor sites by
recruiting and activating NK cells.
Gene therapy using CX3CL1 gene could activate T cells as
well as NK cells to exert its antitumor responses [104–106].
Moreover, intratumoral injection of a DNA plasmid coding
for a chimeric immunoglobulin combining with CX3CL1
chemokine domain provided strong antitumor activity [107].
The administration of this fusion proteinwith tumor antigens
induced a strong in vivo antigen-specific T-cell proliferation
and effector function, accompanied with myeloid DC accu-
mulation [107]. Thus, CX3CL1 can redirect T cells and DCs
as well as NK cells, thereby augmenting adaptive immunity
to tumor antigens.
In order to enhance the capacity to move to tumor
sites by utilizing the chemokine(s) produced by tumor cells,
several groups genetically engineered T cells to express the
corresponding chemokine receptor.The Reed-Sternberg cells
of Hodgkin lymphoma predominantly produce CCL17 and
CCL22 [108]. Effector CD8+ T cells lack CCR4, but CCR4
gene-modified CD8+ T cells migrated more efficiently to
Hodgkin lymphoma site to inhibit tumor formation [109].
Similarly, CCL2 was highly secreted by malignant pleural
mesothelioma cells, and CCR2 gene was further transduced
to activate human T cells expressing a chimeric antibody
receptor (CAR) directed to mesothelioma tumor antigen,
mesothelin (mesoCAR T cells) [110]. The resultant gene-
modified T cells exhibited enhanced antitumor responses
accompanied with augmented T-cell infiltration into tumor
sites, when they were given intravenously [110]. This novel
gene therapy technology using a chemokine receptor can
effectively enhance the migration of adoptively transferred T
cells into tumor sites, where a corresponding chemokine is
expressed abundantly.
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4.2. Reversal of Suppressor Cell-Mediated Immune Suppres-
sion. Tumor immunity can frequently induce immune sup-
pressive mechanisms to reduce the “immunity to self ” by
the action of several negative immunoregulatory receptors
such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and the
programmed death receptor-1- (PD-1-) PD ligand-1 (PD-L1)
axis. Consequently, the antagonizing monoclonal antibodies
to CTLA-4, PD-1, or PD-L1 are effective against various
types of cancer even at advanced stages [111, 112]. These
observations indicate that reversal of immune suppression
can be effective to enhance tumor immunity.
Tumor tissues contain the leukocytes that can diminish
tumor immunity. The most predominant subset is TAMs
[8, 12]. TAMs can promote tumor progression by induc-
ing angiogenesis and suppression of adaptive and innate
antitumor immunity (Figure 1). Circulating monocytes are
mostly the precursor of these TAMs and are attracted into
tumor sites, by several chemokines, particularly CCL2 [8,
12]. Indeed, systemic delivery of neutralizing anti-CCL2
antibody attenuated tumor burdens in human prostate
cancer-bearing mice although its effects on TAMs have not
been examined [113]. Moreover, CCL2 blockade reduced
CCR2-expressing TAM infiltration and eventually tumor
formation in chronic colitis-associated carcinogenesis [10].
Furthermore, CCL2 also recruited monocytes to pulmonary
metastatic sites of murine breast cancer to promote the
extravasation of tumor cells, a prerequisite step formetastasis,
in monocyte-derived VEGF-dependent manner [11]. CCL2
blockade markedly reduced lung metastasis together with
reduced monocyte/macrophage infiltration.
Another type of immune suppressor cells is MDSCs with
a strong ability to suppress various T-cell functions [13].
CCL2 recruits MDSCs in several types of mouse cancer [14].
Moreover, CCL2-mediated MDSC accumulation can nega-
tively regulate the entry of adoptively transferred activated
CD8+ cells into tumor sites [114]. CCR2 deficiency, however,
caused conversion of theMDSC phenotype to neutrophil lin-
eage without affecting tumor growth [15], probably because
MDSC contains a subset of immature neutrophils [115].
On the contrary, CXCR2 blockade reduced the infiltration
of CXCR2-expressing granulocytic MDSCs and eventually
tumor growth in chronic colitis-associated colon cancer [16].
Adult T-cell leukemia (ATL) cells are characterized by
robust expression of CCR4 and canmigrate in vitro to CCL17
andCCL22, ligands for CCR4 [81]. Humanized defucosylated
monoclonal antibody to CCR4 has been obtained. The resul-
tant antibody can exert more potent antibody-dependent
cytotoxicity (ADCC) [116] and is capable of removing CCR4-
expressing ATL cells in peripheral blood and bone marrow
mainly by ADCC.
A large number of Treg cells often infiltrate into tumors
and systemic removal of Treg cells enhances natural as well
as vaccine-induced antitumor T-cell immunity [17]. Treg cells
express CCR4 and its ligand, CCL22, mainly regulates intra-
tumoral Treg infiltration in various tumors [17] (Figure 2).
Indeed, intratumoral CCL22 expression correlated well with
Foxp3 expression in colorectal carcinoma tissues [117]. In
line with these observations, anti-CCR4 antibody treatment
depletes Tregs and eventually evokes CD8+ T-cell response
against TAAs [118]. Furthermore, CCL2 is also involved in
Treg accumulation and, as a consequence, anti-CCL2 anti-
body augmented cancer immunotherapy against non-small
cell lung cancer in mice with reduced intratumoral Tregs and
increased numbers of intratumoral antigen-specific activated
CD8+ cells, when it was administered in combination with
a tumor vaccine [119]. These observations illustrate that
targeting these chemokines can reduce intratumoral Treg
cells, resulting in the enhancement of tumor immunity.
Recently, CCR1-expressing CD34+ immature myeloid
cells have been detected in murine intestinal tumors with
SMAD4 deficiency [120]. These cells expressed abundantly
MMP-9 and MMP-2 and were involved in invasion. More-
over, a CCR1 antagonist suppressed colon cancer liver metas-
tasis by blocking accumulation of CD34+ immature myeloid
cells [121].
4.3. Other Strategies of AntitumorTherapy Targeting Chemok-
ines. Neovascularization is crucial for tumor growth, pro-
gression, and metastasis [36]. The ELR motif-positive CXC
chemokines, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6,
CXCL7, and CXCL8, can directly promote the migration and
proliferation of endothelial cells and eventually neovascular-
ization [37] (Figure 4). Indeed, the administration of anti-
CXCL8 reduced the tumor sizes of humannon-small cell lung
cancer cells which are injected into severe combined immune
deficient (SCID) mice in advance [122]. The reduction in
tumor size was associated with a decline in tumor-associated
vascular density and was accompanied by a decrease in
spontaneous lung metastasis. CXCL12 [123] and three CC
chemokines, CCL2, CCL11, and CCL16, have also been
implicated in tumor neovascularization [39–41, 45].However,
it still remains elusive on the efficacy of targeting these
chemokines for the control of tumor neovascularization.
CXCL4, CXCL9, CXCL10, and CXCL11 inhibit the angio-
genesis induced by ELR motif-positive CXC chemokines,
VEGF, and bFGF [42, 43]. Targeted expression of CXCL9 or
intratumoral CXCL9 administration retarded in vivo tumor
growth by inhibiting tumor-derived angiogenesis [26, 124].
Thus, these chemokines can be effective for tumor therapy
by inhibiting neovascularization as well as inducing CXCR3-
expressing cytotoxic T-cell infiltration.
5. Concluding Remarks
Cancer development and progression are profoundly affected
by inflammatory and immune responses. Inflammatory
responses consist of leukocyte infiltration, neovasculariza-
tion, and fibrosis, while immune responses were exerted
by immune cells such as lymphocytes and dendritic cells.
Chemokines have great impacts on the cells involved in
both inflammatory and immune responses.Moreover, several
chemokines have direct effects on the proliferative and
invasive properties of tumor cells. Consequently, chemokines
play crucial roles in tumor development and progression
by acting on cancerous and noncancerous cells. However,
it is embarrassing that the same chemokine can induce
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tumor progression as well as protection against a tumor, in a
context-dependent manner. Given the multifactorial roles of
chemokines in carcinogenesis, the elucidation of their roles
will further advance our understanding of the pathophysio-
logical processes of tumor development and progression and
will subsequently pave a novel way to develop a novel type of
anticancer treatment by targeting chemokines.
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